Citations

Clear

1828 citation(s) found for "Su, Emily".

Chromosome X-wide association study in multiple system atrophy identifies sex-differential risk loci
Ray, Anindita , Chia, Ruth , Rasheed, Memoona, Ece, Bayram, Jinhui, Ding, Walton, Ronald L., Diez-Fairen, Monica, Álvarez, Ignacio Morales, Fanciulli, Alessandra , Seppi, Mag Klaus, Duerr, Susanne, Leys, Fabian , Krismer, Florian , Sidoroff, Victoria , Pirker, Walter , Rascol, Olivier, Foubert-Samier, Alexandra, Meissner, Wassilios G, Tison, François , Barone, Paolo, Russillo, Maria Claudia, Marín-Lahoz, Juan, Kulisevsky, J, Torres, Soraya, Mir, Pablo, Periñán, María Teresa, Proukakis, C., Goh, Yee Yen, Parkkinen, Laura, Hu, Michele T, Saxon, Jennifer A. , Rollinson, Sara , Garland, Emily M. , Litvan, Irene, Alcalay, Roy N, Kwei, Kimberly , Lubbe, Steven, Mao, Qinwen, Flanagan, Margaret E, Castellani, Rudolph J, Ndayisaba, Alain , Calvo, Andrea, Canosa, Antonio, Bohannan, Ryan C., Norcliffe-Kaufmann, Lucy, Palma, Jose-Alberto, Dawson, Ted M, Albert, Marilyn S, Pletniková, Olga , Troncoso, Juan C, Lage, Carmen , Sánchez-Juan, Pascual, Serrano, Geidy E, Beach, Thomas G, Morris, Huw R, Clarimon, Jordi, Jaunmuktane, Zane, Révész, Tamás, Warner, Tom, Hardy, John A, Ryten, Mina, Ferrucci, Luigi, Topol, Eric, Torkamani, Ali, DeCasien, Alex R, Chiò, Adriano, Low, Philip, Wszolek, Zbigniew K, Dickson, Dennis W., Traynor, Bryan J, Gibbs, J Raphael, Dalgard, Clifton L, Ross, Owen A, Houlden, Henry, Scholz, Sonja W., Hardy, John , Dickson, Dennis W. , Ross, Owen A. , Houlden, Henry , Scholz, Sonja W. , Chia, Ruth , Proukakis, Christos , Dickson, Dennis W , Dalgard, Clifton L , Ross, Owen A , Houlden, Henry , Scholz, Sonja W , Hardy, John , Reynolds, Regina H. , Díez-Fairén, Mónica , Fanciulli, Alessandra , Stefanova, Nadia , Seppi, Klaus , Krismer, Florian, Zimprich, Alexander , Rascol, Olivier , Foubert‐Samier, Alexandra , Meissner, Wassilios G. , Tison, François , Traon, Anne Pavy‐Le , Pellecchia, Maria Teresa , Marín‐Lahoz, Juan , Kulisevsky, Jaime , Mir, Pablo , Chelban, Viorica , Wu, Lesley , Kobylecki, Christopher , Biaggioni, Italo , Litvan, Irene , Rubio, Ileana, Lubbe, Steven , Flanagan, Margaret E , Castellani, Rudolph J. , Khurana, Vikram , Mora, Gabriele , Floris, Gianluca , Moore, Anni K. , Norcliffe‐Kaufmann, Lucy , Palma, Jose-Alberto , Kaufmann, Horacio , Dawson, Ted M , Rosenthal, Liana S. , Pantelyat, Alexander , Troncoso, Juan C. , Infante, Jon , Serrano, Geidy E. , Beach, Thomas G. , Pástor, Pau , Albani, Diego , Clarimón, Jordi , Jaunmuktane, Zane , Frontzek, Karl , Warner, Thomas T. , Ferrucci, Luigi , Topol, Eric J. , Torkamani, Ali , DeCasien, Alex R. , Chiò, Adriano , Singer, Wolfgang , Cheshire, William P. , Wszołek, Zbigniew K. , Traynor, Bryan J. , Gibbs, J. Raphael

Mayo Clinic

Brain | February 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag062 | PMID 41684229 Get It

Abstract The human X chromosome accounts for ∼5% of the genome. Despite its size, the role of X-chromosomal variants in human diseases is not well understood, mainly due to its distinct inheritance pattern and the frequent omission of sex chromosomes from genome-wide association studies. This study used whole-genome sequencing data from 888 multiple system atrophy (MSA) cases and 7128 controls to perform an X-chromosome-wide common variant association study. Our analyses revealed two sex-differential risk loci: one located at Xq28, associated with increased risk for MSA in females [index variant: rs4898389, odds ratio (OR) = 1.69, 95% confidence interval (CI) = 1.40–2.03, P-value = 2.43 × 10⁻⁸], and another at Xp22.2 within the TBL1X gene, identified in males (index variant: rs6638956, OR = 1.48, 95%CI = 1.26–1.73, P-value = 9.92 × 10⁻⁷). In the Xq28 locus, colocalization analyses pointed to FAM3A and PLXNA3 as genes of interest. These findings emphasize the vital role of sex-differential genetic factors in the pathogenesis of MSA.
Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Abu-Rustum, Nadeem R, Campos, Susana M. , Amarnath, Sudha R. , Barber, Emma L. , Bradley, Kristin, Brooks, Rebecca , Chon, Hye Sook, Crispens, Marta Ann, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Glaser, Scott , Howitt, Brooke E. , Kendra, Kari , Mantia-Smaldone, Gina , Mariani, Andrea , Mutch, David, Nagel, Christa , Nekhlyudov, Larissa, Nwachukwu, Chika, Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Schuetze, Scott M. , Siedel, Jean , Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Nwachukwu, Chika , Abu‐Rustum, Nadeem R. , Arend, Rebecca C. , Bradley, Kristin , Chino, Junzo , Crispens, Marta Ann , Gaillard, Stéphanie , Glaser, Gretchen , Landrum, Lisa M. , Lea, Jayanthi Sivasothy , Lee, Nita Karnik , Mutch, David G. , Nekhlyudov, Larissa , Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 3 | Pages: 101-126

10.6004/jnccn.2026.0011 | PMID 41825134 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vaginal Cancer outline the recommended diagnostic workup, staging considerations, and treatment options for this rare malignancy. Because vaginal cancer is uncommon and shares many biologic and clinical characteristics with cervical cancer, several management recommendations, particularly systemic therapy, are extrapolated from evidence and practices established for cervical cancer. This guideline excerpt summarizes key components of management, including diagnostic evaluation and workup, principles of staging, pathology considerations, radiation therapy principles, and primary treatment recommendations for both early-stage and advanced disease. It also details approaches to manage relapses, including locoregional recurrence and distant metastases, and provides an in-depth overview of systemic therapy recommendations for vaginal cancer.
AI-generated data contamination erodes pathological variability and diagnostic reliability
Liu, Dianbo, He, Hongyu , Xiang, Shaowen, Zhang, Ye, Zhu, Yingtao, Zhang, Jin, Lu, Yunyi, Deng, Hao , Alsentzer, Emily, Liu, Yun, Chen, Qingyu , Yu, Kun‐Hsing , Marshall, Andrew, Chen, Tingting, Anumasa, Srinivas, Ebner, Daniel, Ho, Dean , Cheng, Ching-Yu, Alsentzer, Emily , Yu, Kun‐Hsing , Ngiam, Kee Yuan , Cheng, Ching‐Yu

Mayo Clinic

No container title available | February 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8753102/v1 Get It

Abstract Generative artificial intelligence (AI) is rapidly populating medical records with synthetic or partially AI-generated content, creating a feedback loop where future models are increasingly at risk of training on uncurated AI-generated data. However, the clinical consequences of this AI-generated data contamination remain unexplored. Here, we show that in the absence of mandatory human verification, this self-referential cycle drives a rapid erosion of pathological variability and diagnostic reliability of medical data at population scale. By analysing more than 800,000 synthetic data points across clinical text generation, vision–language reporting, and medical image synthesis, we find that models progressively converge toward generic phenotypes regardless of the model architectures. Specifically, rare but critical findings, including pneumothorax and effusions, vanish from the synthetic content generated by AI models, while demographic representations skew heavily toward middle-aged male phenotypes. Crucially, this degradation is masked by false diagnostic confidence. Models continue to issue reassuring reports while failing to detect life-threatening pathology, with false reassurance rates tripling to 40%. Blinded physician evaluation confirms that this decoupling of confidence and accuracy renders AI-generated documentation clinically useless after just two generations. We systematically evaluate three mitigation strategies that can be easily integrated into existing clinical workflows, finding that while synthetic volume scaling fails to prevent collapse, mixing real data with quality-aware filtering effectively preserves diversity. Ultimately, our results suggest that without policy-mandated human oversight, the deployment of generative AI threatens to degrade the very healthcare data ecosystems it relies upon.
Indocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients: A Pediatric Surgical Oncology Research Collaborative prospective observational study
Schermerhorn, Sophia M. V. , Vore, Emily , Bondoc, Alexander J, Ayala, Samantha, Kastenberg, Zachary J. , Arkin, Cameron, Malek, Marcus M. , Campwala, Insiyah, Aldrink, Jennifer H. , Horvath, Kyle , Piché, Nelson , Osman, Yasmin, Brown, Erin G, Doyle, Kathleen, Abril, Paige, Roach, Jonathan P, Ziogas, Ioannis A. , Rhee, Daniel S. , Chidiac, Charbel, Debertin, Julia , Craig, Brian T. , Lee, W. N., Barkhordar, Aaron, Joshi, Devashish , Stellon, Michael , Davies, Dafydd A., Boehmer, Chloé , Dasgupta, Roshni, Kastenberg, Zachary J , Arkin, Cameron , Malek, Marcus M , Aldrink, Jennifer H , Horvath, Kyle Z , Polites, Stephanie F. , Lee, William G , Barkhordar, Aaron , Joshi, Devashish , Beckhorn, Catherine , Dasgupta, Roshni , Bondoc, Alexander , Lautz, Timothy B. , Campwala, Insiyah , Brown, Erin G. , Roach, Jonathan P. , Chidiac, Charbel , Lal, Dave R. , Kim, Eugene S. , Le, Hau D. , Tracy, Elisabeth T. , Beckhorn, Catherine B , Dasgupta, Roshni

Mayo Clinic

Cancer | February 7, 2026 | Volume: 132 | Issue: 4 | Pages: No page available

10.1002/cncr.70274 | PMID 41653066 Get It

ABSTRACT Background Sentinel lymph node (SLN) biopsy is a critical staging tool in skin and soft tissue cancers. Although technetium lymphoscintigraphy is the most common adjunct, indocyanine green (ICG) demonstrates a promising alternative in pediatric, adolescent, and young adult (AYA) skin and soft tissue cancers. Methods and Objectives Evaluate the safety and efficacy of ICG in SLN biopsy (SLNB) in diverse pediatric and AYA solid cancers in a multi‐institutional environment. This is a prospective, observational study conducted at 13 member institutions in the Pediatric Surgical Oncology Research Collaborative between 2019 and 2023. Eligible patients underwent SLNB for primary or recurrent solid skin and soft tissue tumors. Peritumoral ICG was administered intraoperatively. Outcomes included SLN detection rates, histopathology of excised specimens, and surgeon‐reported assessment of utility. Safety was assessed through adverse event reporting. Results Forty SLNB procedures yielded 84 specimens: 13 melanoma (32.5%), 12 squamous cell carcinoma (30%), 11 non‐rhabdomyosarcoma soft tissue sarcoma (27.5%), two rhabdomyosarcoma (5%), one Ewing sarcoma (2.5%), and one malignant peripheral nerve sheath tumor (2.5%). Histologic evaluation identified 81 lymph nodes, 75 benign (89.3%) and six malignant (7.1%); three specimens were adipose tissue (3.6%). Of 81 lymph nodes, 76% were ICG‐positive. ICG had a sensitivity of 79.5%, a specificity of 33%, and a positive predictive value of 96%. All malignant nodes were ICG‐avid. There were no adverse reactions to ICG at 30 days. Conclusions ICG is a safe and effective adjunct for SLNB in pediatric and AYA soft tissue and skin malignancies.
Cerebrospinal Fluid Metagenomic Next-Generation Sequencing in Pediatric Central Nervous System Infection: Clinical Experience and Diagnostic Stewardship Strategies
Li, Guyu , Zhang, Ziyuan , Rajapakse, Nipunie , Ristagno, Elizabeth H. , Rodning, Amanda A, Simner, Patricia J. , Gaensbauer, James , Patel, Robin, Patel, Robin , Puumala, Emily , Zhang, Ziyuan , Rajapakse, Nipunie S , Ristagno, Elizabeth H , Wolf, Matthew J, Simner, Patricia J , Gaensbauer, James T , Patel, Robin , Wolf, Matthew J

Mayo Clinic

Open Forum Infectious Diseases | February 4, 2026 | Volume: 13 | Issue: 2 | Pages: No page available

10.1093/ofid/ofag054 | PMID 41743993 Get It

Abstract Background Identification of the microorganisms causing infection in children with central nervous system infection is important. Conventional cerebrospinal fluid (CSF) tests may provide limited pathogen detection. CSF metagenomic next-generation sequencing (mNGS) may provide broader pathogen detection in a single assay. Methods Results of CSF mNGS testing performed at Mayo Clinic on patients and nonpatients between January 2024 and June 2025 were retrospectively analyzed. The subcohort of children treated at Mayo Clinic was analyzed to assess test performance as compared with conventional CSF diagnostics and potential clinical impact. Results In total 134 patients (138 CSF mNGS tests) from 22 US states and 2 international sites were included. Overall positivity was 16% with viruses representing most (59%) detections. In the Mayo Clinic subcohort (n = 15), test positivity was 27%: organisms included single detections of Streptococcus mitis group and HIV type 1, as well as 2 detections of Epstein-Barr virus, all confirmed by conventional tests. Positive results were associated with CSF pleocytosis (P = .026). Higher yield was observed in participants whose care was overseen by pediatric infectious diseases (PID) specialists (P = .026) and when a specimen hold strategy was applied (P = .033). Most results (87%) did not alter antimicrobial therapy, with 2 negative results contributing to antimicrobial de-escalation. Conclusions CSF mNGS demonstrated higher diagnostic yield in patients whose specimens showed CSF pleocytosis and in those who had PID consultation. Diagnostic stewardship strategies were applied, including specimen hold approaches and PID consultation.
Serous Ovarian Cancer Following Opportunistic Bilateral Salpingectomy
Sowamber, Ramlogan , Mei, Alice J. , Kaur, Paramdeep, McLeod, Julianne, McKay, Emily , Lukey, Alex, Bakkum-Gamez, Jamie, Buza, Natalia, Cohen, Paul A., Farrell, Rhonda, Garcia, Christine, Gilks, Blake, Goode, Ellen, Howitt, Brooke, Hui, Pei, Köbel, Martin , Kushi, Lawrence, Kwon, Janice, Long-Roche, Kara C., Malpica, Anais, McAlpine, Jessica N., Miller, Dianne , Oliva, Esther, Paliga, Aleksandra, Parra-Herran, Carlos, Pearce, Celeste Leigh , Piek, Jurgen Martinus, Qiu, Haiyan, Rabban, Joseph T. , Rome, Robert, Steenbeek, Miranda, Stone, R., Talhouk, Aline , Tischer, Kristin M., Huntsman, David G., Howitt, Brooke E. , Cohen, Paul A. , Piek, Jurgen M.J. , Tischer, Kristin M. , Köbel, Martin , Cohen, Paul , Kaur, Paramdeep , Bakkum‐Gamez, Jamie N. , Buza, Natália , Devins, Kyle M. , Farrell, Rhonda , Garcia, Christine , Gilks, C. Blake , Goode, Ellen L. , Hodgson, Anjelica , Hui, Pei, Huvila, Jutta , Karnezis, Anthony N. , Keyhanian, Kianoosh , Kinloch, Mary A. , Kommoss, Felix , Kushi, Lawrence H. , Kwon, Janice S. , Malpica, Anais, McAlpine, Jessica N. , Oliva, Esther , Palicelli, Andrea , Parra‐Herran, Carlos , Perera, Sharnel , Steenbeek, Miranda, Tischer, Kristin M. , Trabert, Britton , Webb, Penelope M. , Zalcberg, John , Huntsman, David G. , Hanley, Gillian E.

Mayo Clinic

JAMA Network Open | February 2, 2026 | Volume: 9 | Issue: 2 | Pages: e2557267

10.1001/jamanetworkopen.2025.57267 | PMID 41627818 Get It

This cohort study evaluates the reduction in risk of high-grade serous carcinoma among women undergoing opportunistic bilateral salpingectomy in Canada.
Relationship between age and severity of cognitive impairment at diagnosis for early‐onset and late‐onset Alzheimer's disease: Comparison of LEADS and ADNI
Hammers, Dustin B., Eloyan, Ani, Thangarajah, Maryanne, Taurone, Alexander, Gao, Sujuan, Beckett, Laurel, Kirby, Kala, Dage, Jeffrey L., Nudelman, Kelly, Aisen, Paul, Reman, Rema, Vemuri, Prashanthi, Joie, Renaud La, Touroutoglou, Alexandra, Atri, Alireza, Clark, David, Day, Gregory S., Duara, Ranjan, Graff‐Radford, Neill R., Honig, Lawrence S., Jones, D., Masdeu, Joseph C. , Mendez, Mario F., Womack, Kyle, Musiek, Erik, Onyike, Chiadi U., Riddle, Meghan, Grant, Ian, Rogalski, Emily, Johnson, Erik C. B., Salloway, Steven, Sha, Sharon J. , Turner, Raymond Scott, Wingo, Thomas S., Wolk, David A., Carrillo, Marı́a C., Dickerson, Bradford C., Rabinovici, Gil D., Apostolova, Liana G., Initiative, for the Alzheimer's Disease Neuroimaging, Carrillo, María C. , Rabinovici, Gil D. , Joie, Renaud La , Day, Gregory S. , Day, Gregory S , La Joie, Renaud , Rabinovici, Gil D , Hammers, Dustin B , Eloyan, Ani , Taurone, Alexander, Gao, Sujuan , Beckett, Laurel , Dage, Jeffrey L. , Nudelman, Kelly , Aisen, Paul , Reman, Rema, Vemuri, Prashanthi , Touroutoglou, Alexandra , Atri, Alireza , Clark, David, Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Mendez, Mario F. , Musiek, Erik , Onyike, Chiadi U. , Riddle, Meghan , Johnson, Erik C. B. , Salloway, Steve , Turner, Raymond Scott , Wolk, David A. , Dickerson, Bradford Clark , Apostolova, Liana G. , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | January 30, 2026 | Volume: 22 | Issue: 2 | Pages: No page available

10.1002/alz.71160 | PMID 41614286 Get It

INTRODUCTION Recent work has identified unique cognitive profiles for early‐onset Alzheimer's disease (EOAD) relative to late‐onset Alzheimer's disease (LOAD), however, examination has been limited in determining whether the association between age and cognitive severity at presentation also differs across conditions. METHODS A series of linear spline regression models was conducted across baseline cognitive data from 325 EOAD and 314 LOAD participants, after accounting for education, sex, and apolipoprotein ε4 status. RESULTS Significant differences existed in the relationship between baseline age and cognitive performance between EOAD and LOAD samples for Processing Speed/Attention, Executive Functioning, and Episodic Immediate Memory. Younger participants from both EOAD and LOAD groups performed disproportionately worse on non‐amnestic cognitive domains, with this occurring to a greater extent in EOAD than LOAD. DISCUSSION In the age of disease‐modifying treatments, results highlight the importance of assessing for cognitive declines in individuals starting much earlier than age 65. Highlights Early‐onset Alzheimer's disease (EOAD) and late‐onset Alzheimer's disease (LOAD) participants each displayed cognitive impairments relative to same‐aged peers across most domains. Both groups displayed positive relationships between impairment among non‐amnestic cognitive domains and baseline age. This relationship displayed a significantly greater effect in EOAD than LOAD, with domains of Processing Speed/Attention and Executive Functioning skills being the most pronounced. Of those participants developing AD, age displayed a disproportionate impact on their symptom onset.
Abstract TP237: Automated large vessel occlusion detection on CT angiography: a prospective comparison of two software packages
Mendis, Dinith , WOLFE, J, Beegle, Richard D. , Sandhu, Johnny S., Demaerschalk, Bart, Nord, Charisse, Pahl, Emily, Wood, Sam, FERNANDEZ, CLAIRE, Woodhead, Zoe VJ, English, Stephen , Demaerschalk, Bart M. , Nord, Charisse A., Carone, Davide , Harston, George

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.tp237 Get It

Introduction: AI-driven software has been recommended as a means of triaging suspected large vessel occlusions (LVOs) on CT angiography (CTA), and different solutions are now commercially available. This study compared the performance of two software packages, Brainomix 360 Triage LVO and Rapid LVO, in prospective, real-world use. Methods: Consecutive patients scanned for suspected stroke at 3 comprehensive stroke centres from May to July 2024 (3 months) were included in the study. CTA, where available, was processed in real time by both Rapid and Brainomix software. Ground truth on vessel occlusion was ascertained using clinical review of electronic medical records. Occlusion location was coded as intracranial internal carotid artery terminus (ICA-T), middle cerebral artery (MCA) M1 or MCA M2. If more than one occlusion was observed, the most proximal of these was taken as the primary vessel affected. Results: There were 561 suspected stroke patients scanned during the study period across the three sites. Of these, CTA was sent for processing by both Rapid LVO and Brainomix 360 Triage LVO for 359 cases. Cases were excluded if no contrast was detected (n=17), leaving 342 cases (Table 1). Of these, proximal LVO (ICA-T or MCA M1) was confirmed in 14 cases and MCA M2 occlusions were present in 6 cases. Table 2 shows the LVO detection results for all cases from the two software packages. For both devices, sensitivity was higher when considering only proximal occlusions (ICA-T or M1). Performance was similar overall, but there was a trend towards differing sensitivity for more distal occlusions. As a composite measure, area under the curve (AUC) was higher for Brainomix than Rapid (Figure 1) but this difference was not significant. The positive predictive value (PPV) was low for both software packages due to the low incidence of LVO in the patient population. Conclusions: This study demonstrated consistent performance of two AI software devices, Brainomix 360 Triage LVO and Rapid LVO, for detection of LVO on CTA imaging, in prospective, real-world use. The low number of positive cases in the dataset (N=21) is a limitation of the study. There was a trend towards different performance for more distal vessel occlusion locations. Overall, the sensitivity observed in this dataset was in line with reports from previous retrospective studies for both software packages and underlines the importance of prospective evaluation to understand real-world performance.
Evaluation of Prophylactic Enoxaparin Anti-Xa Levels in Individuals ≥150 kg
Olson, Logan M. , Wells, Shelby, Peppard, William , Lyden, Elizabeth R., Cantrell, Emily, Peters, Bradley J. , Peters, Bradley J., Lyden, Elizabeth

Mayo Clinic

Thrombosis and Haemostasis | January 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2791-6535 | PMID 41605426 Get It

Abstract Optimal dosing of prophylactic enoxaparin for individuals ≥150 kg is unknown due to limited inclusion in previous studies. Estimate an optimal weight-based prophylactic enoxaparin dose for individuals ≥150 kg. This multicenter, retrospective study included ≥150 kg adult patients admitted to the hospital between January 2014 and April 2024, who received twice daily prophylactic enoxaparin (goal peak anti-Xa 0.2–0.4 IU/mL). At least one peak anti-Xa was required, obtained 3 to 5 hours after the 3rd consecutive dose. The primary outcome was the range of dosing that produced goal prophylactic peak anti-Xa following linear regression modeling. Secondary outcomes were hospital and intensive care unit (ICU)/progressive care unit (PCU) length of stay (LOS), in-hospital mortality, and VTE/bleed events within 72 hours after an eligible peak anti-Xa. A total of 311 encounters and 388 peak anti-Xa levels were assessed. Patients were 46 (37–55) years old, 53.1% were male, and weighed 183.3 kg (166.1–204.1) with a BMI of 61.3 kg/m2 (54.8–69.4). Creatinine clearance was 179.6 mL/min (126.5–228.2) and patients received 4 doses (4–6) before peak anti-Xa, with a time between of 249 minutes (227–271). Linear regression modeling revealed a statistically significant correlation (r2 = 0.27) between weight-based dose and peak anti-Xa (p < 0.0001). Enoxaparin 0.34 mg/kg (95% CI 0.33–0.36) twice daily was predicted to achieve a peak anti-Xa of 0.3 IU/mL. Hospital LOS was 8 days (4–15), ICU/PCU LOS was 8 days (4–14, n = 158), and only two patients (0.6%) died during hospitalization. One VTE event was observed. Our results suggest an appropriate empiric weight-based prophylactic enoxaparin dose for hospitalized patients ≥150 kg is 0.34 mg/kg twice daily.